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amongst melioidosis patients. The potential strengths offered by
metabolomics for infectious disease research will be discussed.
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Methods: One thousand three hundred ﬁfty two blood culture
equests from neonates were analyzed for a period of one year
n a referral tertiary hospital in Sharjah, United Arab Emirates.
acteriological proﬁles were obtained from BacT/ALERT® 3D sys-
em. Identiﬁcation and susceptibilities studies were completed by
icroScan Walk-Away®. Risk factors for sepsis in the neonates
ere recorded.
Results: Blood culture was positive in 61 (4.5%) of cases. Gram-
egativebacteremiawasencountered in61%of theculture-positive
ases. Escherichia coli and Klebsiella species were the predominant
athogens amongst gram-negativeorganisms.Most gram-negative
rganismswere sensitive to carbapenems including imipenem and
eropenem, tigecycline, and ceftriaxone. Themost common gram-
ositive organism isolated was Staphylococcus aureus (26%). All
ram-positive were sensitive to vancomycin and tigecycline. The
ost important risk factor of bacteremia in our study population
as preterm birth (53%).
Table 1:Distribution of bacterial isolates
Organism isolated No. of cases
Gram positive Staphylococcus aureus 16
Coagulase negative staphylococci 01
Enterococcus species 03
Streptococcus aglacitae 03
Streptococcus pyogenes 01
Gram negative Escherichia coli 16
Enterobacter species 02
Klebsiella species 07
Salmonella species 03
Acinetobacter species 03
Stenotrophomonas maltophilia 01
Pseudomonas species 04
Chryseobacterium meningosepticum 01
Total isolates 61
Table 2: Sensitivity pattern of the Gram-positive isolates
Antibiotics Staphylococcus
aureus (n =16)
other
Gram-positive
organisms
(n=8)
Amoxycillin 7 (40) 6(75)
Penicillin 0(0) 6 (75)
Tigecycline 16 (100) 8 (100)
Vancomycin 16 (100) 8 (100)
Co-trimoxazole 13(82) 6(75)
Ciproﬂoxacin 12 (75) -
.B. (-) means that it has not been done; Figures in parentheses are in percentage
Table 3: Sensitivity pattern of the Gram-negative isolates (per-
entage sensitive)
Antibiotics E.coli
(n = 16)
Entero
(n =2)
Klebsiella
(n =7)
Salmonella
(n =3)
Acineto
(n=3)
Pseudo
(n=4)
Tigecycline 16(100) 2(100) 7(100) 3(100) 0 (0) -
Ceftriaxone 13(81) 2(100) 4(58) 3100) 0(0) 3(75)
Cefotaxime 11(69) 1(50) 4(58) 3(100) 0(0) 0(0)
Imipenem 16(100) 2(100) 7(100) 3(100) 3(100) 4(100)
Meropenem 16(100) 2(100) 7(100) 3(100) 3(100) 4(100)
Gentamicin 08(50) 2(100) 3(42) - 0(0) 4(100)
Amikacin 10(62) 2(100) 3(42) - 1(33) 4(100)
Ciproﬂoxacin 13(81) 1(50) 5(71) 3 (100) 0(0) 3(75)
N.B. (-) means that it has not been done.Conclusion: From the
usceptibility pattern it appears, tigecycline, imipenam and third
eneration cephalosporins have replaced amoxicillin-clavulanic
cid, co-trimoxazole, and gentamicin plus beta-lactam as suitable
gents for empiric therapy of neonatal blood stream infections in
ur setup. However, due to limitations in our sample size, we will
ontinue to perform periodic antimicrobial susceptibility surveil-
ance to create a dynamic database useful to the local physician in
reating neonatal blood stream infections.
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Background: The current diagnostic arsenal for infectious dis-
eases is predominantly based on pathogen-detection, but is deﬁed
by many lethal pathogens that can cause disease while being
hidden in the body or simply undetectable. Metabolomics has
great potential to offer new diagnostic solutions as it provides
the possibility to identify new disease biomarkers in the form of
pathogen-responsive metabolites in body ﬂuids that can be trans-
lated to bedside diagnostics. In addition, metabolite biomarkers for
disease could further point out which human metabolic processes
aredisruptedby the infectingpathogenandas suchprovide abetter
understanding of the underlying disease. We here present a study
that evaluates metabolomics as an applied research strategy for
improving infectious disease control. Our work focuses on the bac-
terial diseasemelioidosis forwhichnewdiagnostic tools areneeded
to reduce its associated morbidity and mortality in Australia and
Southeast Asia.
Methods: Blood samples for metabolic proﬁling were col-
lected in the melioidosis hyperendemic Khon Kaen Province in
Thailand from (i) non-infected controls, (ii) patients with bac-
teremia due to other bacteria, and (iii) bacteremic melioidosis
patients. Bloodplasmawasanalyzedbygas-chromatographymass-
spectrometry (GC-MS) to characterize the polar metabolites, and
liquid-chromatography mass-spectrometry (LC-MS) to character-
ize the non-polar metabolites.
Results: The current results suggest that plasma metabolic
proﬁles can robustly differentiate bacteremic melioidosis patients
from patients suffering from other bacterial blood infections and
healthy controls from the same endemic region. Various com-
pounds were found to have a characteristic proﬁle in melioidosis
patients and represent new candidate diagnostic biomarkers for
this lethal disease.
Conclusion: We will present these ﬁndings in the con-
text of diagnostic biomarker discovery and highlight the
power of metabolic proﬁling to reveal pathogenetic differences
